ANI PHARMACEUTICALS, INC (ANIP) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.10%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.20%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.10% | Research and development expense / revenue. Period ending 2026-06-30. $49.91M ÷ $978.38M × 100 ≈ 5.10% |
| Stock-based compensation / revenue · 12 months | 4.20% | Share-based compensation / revenue. Period ending 2026-06-30. $41.06M ÷ $978.38M × 100 ≈ 4.20% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 49.91M USD | Research and Development Expense |
| Revenue | 978.38M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 41.06M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 150.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.91M | $978.38M | $41.06M | $150.35M | (m) | 5.10% | 4.20% | (m) | (m) |
| 2026-03-31 | $51.70M | $923.71M | $39.25M | $123.79M | (m) | 5.60% | 4.25% | (m) | (m) |
| 2025-12-31 | $51.66M | $883.37M | $37.93M | $111.09M | (m) | 5.85% | 4.29% | (m) | (m) |
| 2025-09-30 | $56.05M | $826.88M | $35.22M | $71.95M | (m) | 6.78% | 4.26% | (m) | (m) |
| 2025-06-30 | $53.87M | $747.40M | $33.02M | $15.19M | (m) | 7.21% | 4.42% | (m) | (m) |
| 2025-03-31 | $44.63M | $674.07M | $31.28M | $6.47M | (m) | 6.62% | 4.64% | (m) | (m) |
| 2024-12-31 | $44.58M | $614.38M | $29.34M | $584.00K | (m) | 7.26% | 4.78% | (m) | (m) |
| 2024-09-30 | $37.80M | $555.46M | $27.90M | $11.69M | (m) | 6.81% | 5.02% | (m) | (m) |
| 2024-06-30 | $38.80M | $538.95M | $25.86M | $50.16M | (m) | 7.20% | 4.80% | (m) | (m) |
| 2024-03-31 | $38.87M | $517.46M | $23.25M | $57.39M | (m) | 7.51% | 4.49% | (m) | (m) |
| 2023-12-31 | $34.29M | $486.82M | $20.65M | $46.97M | (m) | 7.04% | 4.24% | (m) | (m) |
| 2023-09-30 | $29.64M | $449.39M | $18.77M | $42.06M | (m) | 6.60% | 4.18% | (m) | (m) |
| 2023-06-30 | $26.18M | $401.39M | $17.19M | $19.12M | (m) | 6.52% | 4.28% | (m) | (m) |
| 2023-03-31 | $22.97M | $358.69M | $15.70M | $-6.19M | (m) | 6.40% | 4.38% | (m) | (m) |
| 2022-12-31 | $22.32M | $316.38M | $14.60M | $-35.28M | (m) | 7.05% | 4.61% | (m) | (m) |
| 2022-09-30 | $20.24M | $283.08M | $13.83M | $-60.83M | (m) | 7.15% | 4.89% | (m) | (m) |
| 2022-06-30 | $15.04M | $251.32M | $12.77M | $-59.39M | (m) | 5.98% | 5.08% | (m) | (m) |
| 2022-03-31 | $13.68M | $226.09M | $11.86M | $-62.03M | (m) | 6.05% | 5.24% | (m) | (m) |
| 2021-12-31 | $11.37M | $216.14M | $10.49M | $-39.79M | (m) | 5.26% | 4.85% | (m) | (m) |
| 2021-09-30 | $11.91M | $212.46M | $9.91M | $-15.74M | (m) | 5.61% | 4.67% | (m) | (m) |
| 2021-06-30 | $12.39M | $213.38M | $9.49M | $-9.38M | (m) | 5.81% | 4.45% | (m) | (m) |
| 2021-03-31 | $12.63M | $213.22M | $12.38M | $-5.13M | (m) | 5.92% | 5.81% | (m) | (m) |
| 2020-12-31 | $16.00M | $208.47M | $12.94M | $-16.02M | (m) | 7.68% | 6.21% | (m) | (m) |
| 2020-09-30 | $17.00M | $199.19M | $12.99M | $-21.02M | (m) | 8.53% | 6.52% | (m) | (m) |
| 2020-06-30 | $19.04M | $197.55M | $13.07M | $-16.49M | (m) | 9.64% | 6.62% | (m) | (m) |
| 2020-03-31 | $21.78M | $203.43M | $9.93M | $4.11M | (m) | 10.70% | 4.88% | (m) | (m) |
| 2019-12-31 | $19.81M | $206.55M | $9.22M | $16.35M | (m) | 9.59% | 4.46% | (m) | (m) |
| 2019-09-30 | $18.61M | $215.70M | $8.60M | $32.47M | (m) | 8.63% | 3.99% | (m) | (m) |
| 2019-06-30 | $18.30M | $215.07M | $7.93M | $35.25M | (m) | 8.51% | 3.69% | (m) | (m) |
| 2019-03-31 | $17.66M | $207.98M | $7.12M | $33.22M | (m) | 8.49% | 3.42% | (m) | (m) |
| 2018-12-31 | $15.39M | $201.58M | $6.78M | $35.36M | (m) | 7.63% | 3.36% | (m) | (m) |
| 2018-09-30 | $14.56M | $191.74M | $6.38M | $31.29M | (m) | 7.59% | 3.33% | (m) | (m) |
| 2018-06-30 | $12.52M | $189.20M | $6.06M | $30.51M | (m) | 6.62% | 3.20% | (m) | (m) |
| 2018-03-31 | $9.55M | $186.70M | $6.08M | $30.24M | (m) | 5.12% | 3.26% | (m) | (m) |
| 2017-12-31 | $9.07M | $176.84M | $6.09M | $28.33M | (m) | 5.13% | 3.44% | (m) | (m) |
| 2017-09-30 | $6.55M | $167.76M | $6.05M | $22.25M | (m) | 3.91% | 3.61% | (m) | (m) |
| 2017-06-30 | $4.96M | $158.12M | $5.94M | $20.84M | (m) | 3.14% | 3.76% | (m) | (m) |
| 2017-03-31 | $3.56M | $144.69M | $6.35M | $19.04M | (m) | 2.46% | 4.39% | (m) | (m) |
| 2016-12-31 | $2.91M | $128.62M | $6.07M | $20.08M | (m) | 2.26% | 4.72% | (m) | (m) |
| 2016-09-30 | $3.43M | $108.45M | $5.83M | $25.05M | (m) | 3.16% | 5.37% | (m) | (m) |
| 2016-06-30 | $3.21M | $89.90M | $5.58M | $25.58M | (m) | 3.57% | 6.21% | (m) | (m) |
| 2016-03-31 | $3.44M | $78.08M | $4.39M | $28.80M | (m) | 4.40% | 5.63% | (m) | (m) |
| 2015-12-31 | $2.87M | $76.32M | $3.86M | $32.70M | (m) | 3.77% | 5.05% | (m) | (m) |
| 2015-09-30 | $2.78M | $79.32M | $3.42M | $37.20M | (m) | 3.51% | 4.31% | (m) | (m) |
| 2015-06-30 | $2.85M | $76.74M | $2.99M | $36.95M | (m) | 3.71% | 3.90% | (m) | (m) |
| 2015-03-31 | $2.71M | $63.87M | $3.94M | $26.08M | (m) | 4.24% | 6.18% | (m) | (m) |
| 2014-12-31 | $2.68M | $55.97M | $3.42M | $20.01M | (m) | 4.78% | 6.12% | (m) | (m) |
| 2014-09-30 | $2.63M | $45.47M | $2.75M | $12.69M | (m) | 5.79% | 6.05% | (m) | (m) |
| 2014-06-30 | $2.21M | $35.91M | $2.06M | $5.30M | (m) | 6.14% | 5.74% | (m) | (m) |
| 2014-03-31 | $1.79M | $35.42M | $83.00K | $3.99M | $374.00K | 5.06% | 0.23% | 10.67× | Reported |
| 2013-12-31 | $1.71M | $30.08M | $36.00K | $898.00K | $467.00K | 5.69% | 0.12% | 1.92× | Reported |
| 2013-09-30 | $17.44M | $6.80M | $728.58K | (m) | $-424.22K | 256.43% | 10.71% | (m) | Reported |
| 2013-06-30 | $17.13M | $4.00M | (m) | (m) | $-342.99K | 428.30% | (m) | (m) | Reported |
| 2013-03-31 | $12.68M | $2.33M | $558.39K | (m) | $288.49K | 543.69% | 23.95% | (m) | Reported |
| 2012-12-31 | $16.89M | $2.30M | $725.63K | $-23.17M | $348.02K | 734.06% | 31.54% | -66.58× | Reported |
| 2012-09-30 | $21.16M | $447.54K | $1.14M | (m) | $448.92K | 4727.14% | 255.53% | (m) | Reported |
| 2012-06-30 | $28.78M | $519.94K | $1.18M | (m) | $553.82K | 5535.87% | 226.71% | (m) | Reported |
| 2012-03-31 | $34.50M | $492.16K | $1.19M | (m) | $633.77K | 7010.13% | 241.86% | (m) | Reported |
| 2011-12-31 | $44.18M | $435.16K | $1.18M | (m) | $681.57K | 10153.11% | 270.63% | (m) | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $39.71M | $2.47M | $992.76K | (m) | $688.08K | 1604.76% | 40.12% | (m) | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $13.68M | $1.26M | $1.25M | (m) | $147.03K | 1087.44% | 99.72% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |